A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
By 2019, two Phase 3 trials of aducanumab were terminated early because the drug wasn’t improving outcomes and was clearly causing harm (a large percentage of the participants were experiencing brain bleeding known as ARIA). And since SSRIs are prescribed for PTSD, this would be a treatment competing with pharmaceutical giants.
127 
Let's personalize your content